| 证券代码：300298 | 证券简称： | 三诺生物 | 公告编号：2024-029 | | --- | --- | --- | --- | | 债券代码：123090 | 债券简称： | 三诺转债 | | 三诺生物传感股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 三诺生物传感股份有限公司（以下简称"公司"或"三诺生物"）于 2024 年 4 月 24 日召开第五届董事会第十次会议和第五届监事会第九次会议，审议通过 了《关于为全资子公司提供担保的议案》，为支持全资子公司三诺健康管理有限 公司（以下简称"三诺健康"）整体业务发展，保障三诺健康及其下属子公司在 生产经营过程中可能产生的融资业务需求，同意公司及合并范围内子公司在风险 可控的前提下，为三诺健康及其合并范围内子公司申请综合授信提供担保，担保 金额不超过人民币 3 亿元，担保期限 3 年，在本次担保额度及担保期限内可循环 滚动使用。在上述担保额度范围内，公司可根据实际情况在三诺健康及其合并范 围内子公司（包括授权期限内新设立或新纳入合并 ...

三诺生物传感股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来的 专项说明 关于三诺生物传感股份有限公司 2023 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2024CSAA2F0021 三诺生物传感股份有限公司 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 1-2 | 三诺生物传感股份有限公司全体股东： 我们按照中国注册会计师审计准则审计三诺生物传感股份有限公司（以下简称三诺 生物公司）2023 年度财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表、 2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变 动表以及财务报表附注，并于 2024 年4 月24 日出具了 XYZH/2024CSAA2B0021 号无保留 意见的审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往来、 对外担保的监管要求》（证监会公告[2022]26 号），以及深圳证券交易所相关披露的要求， 三诺生物公司编制了本专项说明所附的三 ...

三诺生物传感股份有限公司 2023 年度 | 索引 | | 页码 | | --- | --- | --- | | 鉴证报告 | | 1-2 | | 关于募集资金 | 2023 年度存放与使用情况的专项报告 | 1-14 | 募集资金年度存放与使用情况鉴证报告 XYZH/2024CSAA2F0022 三诺生物传感股份有限公司 募集资金年度存放与使用情况鉴证报告 三诺生物传感股份有限公司全体股东： 我们对后附的三诺生物传感股份有限公司(以下简称三诺生物公司)关于募集资金 2023 年度存放与使用情况的专项报告（以下简称募集资金年度存放与使用情况专项报告） 执行了鉴证工作。 三诺生物公司管理层的责任是按照深圳证券交易所相关规定编制募集资金年度存放 与使用情况专项报告。这种责任包括设计、实施和维护与募集资金年度存放与使用情况专 项报告编制相关的内部控制，保证募集资金年度存放与使用情况专项报告的真实、准确 和完整，以及不存在由于舞弊或错误而导致的重大错报。我们的责任是在实施鉴证工作的 基础上，对募集资金年度存放与使用情况专项报告发表鉴证意见。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号-历史财务信息审计或 ...

三诺生物传感股份有限公司 三诺生物传感股份有限公司 2023 年度财务决算报告 2023 年度，在公司董事会的领导下，通过管理层和全体员工的不断努力，较 好地完成了公司的经营目标和计划，现根据信永中和会计师事务所（特殊普通合 伙）出具的 2023 年度审计报告（XYZH/2024CSAA2B0021），编制了公司 2023 年度财务决算报告，具体情况报告如下： 一、2023年度公司主要财务指标 公司继续推动以血糖监测产品为核心的慢性病快速检测业务保持稳健增长， 努力培育以 CGM 为基础的第二曲线成长。同时，公司实现了对美国子公司 Trividia Health Inc.（以下简称"Trividia"）的控股，通过深化细化资源共享、协 同增效，共同推动公司糖尿病管理专家的数智化转型；完善企业信息化建设持续 改进和优化核心业务，提升运营效率和质量，重视对产品研发的投入和自身研发 综合实力的提升，确保公司行业技术引领和核心竞争力。 2023 年度，公司实现营业总收入 405,878.60 万元，较上年同期增长 2.69%。 利润总额和归属于上市公司股东的净利润同比下降，主要原因是： 1、报告期内，三诺聚焦以血糖监 ...

三诺生物传感股份有限公司 董事会审计委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况报告 首席合伙人：谭小青先生 截止 2023 年 12 月 31 日，信永中和合伙人（股东）245 人，注册会计师 1,656 人。签署过证券服务业务审计报告的注册会计师人数超过 660 人。 （二）聘任会计师事务所履行的程序 2023 年 10 月 16 日，公司召开第五届董事会审计委员会第四次会议，审议 并通过《关于续聘 2023 年度审计机构的议案》，同意继续聘请信永中和会计师事 务所（特殊普通合伙）为公司 2023 年度审计机构，并同意将该事项提交公司董 事会审议。 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 根据《公司法》、《证券法》、《上市公司治理准则》、《国有企业、上市公司选 聘会计师事务所管理办法》、《深交所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》和三诺生物传感股份有限公司（以下简称"公司"）的《公司 章程》、《公司董事会专门委员会工作细 ...

Global Market Presence and Sales Network - The company has established a sales and service network covering over 220,000 terminals in mainland China and 135 countries globally through its subsidiaries PTS and Trividia[3] - The company's products have completed registration in 85 countries and regions, meeting global market demands[5][7] - The company holds over 50% of China's blood glucose meter retail market, covering 3,500 hospitals, 220,000 pharmacies, and 9,000 community hospitals, with over 50% of diabetes self-monitoring patients in China using its products[43] - The company has over 25 million users globally, with operations in 135 countries and product registrations in 85 countries[43] - The company has established a global sales network covering 135 countries and regions through the collaborative sales of Sinocare, PTS, and Trividia products[168] Product Portfolio and Innovation - The company's iPOCT system can detect over 70 indicators related to diabetes and chronic diseases[17] - The company's product portfolio includes various series of home glucose monitoring systems, uric acid monitoring products, and dual-function glucose/uric acid testers[18] - The iCARE portable fully automatic multi-function tester can currently detect over 70 indicators, covering more than 2000 diseases including diabetes, inflammation, coagulation, digestion, liver function, and kidney function[20] - The company's products include the High-Sensitivity Troponin I (hs-cTnI) Detection Kit and Zinc Transporter 8 (ZnT8) Antibody Detection Kit, both classified as Class II medical devices[53] - The Glycated Hemoglobin Detection Kit is used for quantitative detection of HbA1c concentration in human whole blood, aiding in diabetes diagnosis and blood sugar monitoring[53] - The company's products also include the Triiodothyronine (T3) Detection Kit and Thyroxine (T4) Detection Kit, both for quantitative detection in serum or plasma[53] - The Anti-Thyroid Peroxidase Antibody (Anti-TPO) Detection Kit is used for quantitative detection of Anti-TPO in serum or plasma[53] - The Myoglobin (MYO) Detection Kit is used for quantitative detection of MYO in serum or plasma[53] - The D-Dimer Detection Kit is used for quantitative detection of D-Dimer in plasma[53] - The company has developed a multi-indicator chronic disease detection product system, focusing on blood glucose and expanding into diabetes-related medical services[43] - The company has established a multi-indicator detection product system based on blood glucose, with 5 product lines and over 20 sub-brands[191] Diabetes and Chronic Disease Management - The company's diabetes management model includes a personalized "AI + Six Disciplines Co-management" approach, involving a team of specialists for comprehensive patient care[3] - The company's global service network and professional medical teams provide end-to-end solutions for diabetes and chronic disease management[4] - The company's diabetes health services include chronic disease system evaluation, standardized treatment, full-course health management, education, and psychological counseling for patients with diabetes, obesity, and hyperuricemia[20] - The company has established a multi-functional chronic disease management center focusing on diabetes reversal through multi-disciplinary interventions and personalized management[20] - The company's diabetes management system integrates "biosensors + internet + medical + services" to achieve full-course management for in-hospital and out-of-hospital patients[26] - The AGEscan advanced glycation end product fluorescence detector uses non-invasive technology to assess future diabetes risk for sub-healthy, high-risk, and pre-diabetic populations[26] - The company aims to expand its market share in diabetes and related chronic disease detection, enhancing its product and service capabilities[116] - The company is focusing on digital transformation, connecting instruments with users, users with data, and data with health service providers to offer comprehensive health management services for diabetes and chronic disease patients[193] Quality Management and Certifications - The company has obtained multiple international certifications, including ISO13485, ISO 9001, CE IVDR, MDR, FDA, and MDSAP[5] - The company's production system is certified under ISO 13485:2016 and complies with Brazil BGMP, US FDA, and EU CE standards, utilizing AI, big data, and BI dashboards for quality and efficiency improvements[22] - In 2023, the company obtained the MDSAP certificate, covering Australia, Brazil, Canada, Japan, and the US, and was selected as a "Hunan Province Manufacturing Quality Benchmark"[22] - The company's procurement system follows strict supplier selection criteria, ensuring quality from the source through a qualified supplier directory[21] - The company implements a centralized procurement system for raw materials, auxiliary materials, and packaging materials, adhering to principles of appropriate price, timing, location, quality, and quantity[21] - The company has established a comprehensive quality management system, including PFMEA, TMV, and QCC, to ensure product safety and stability[25] - The company has established an international quality management system that complies with ISO 13485, ISO 9001, and other relevant regulations and standards, but faces potential quality control risks as production scales up[155] - A Quality Management System (QMS) has been implemented to integrate complaint systems across various channels, enabling unified data management and analysis for customer complaints[171] Financial Performance and Investments - Cash and cash equivalents decreased compared to the same period last year, mainly due to a reduction in net cash flow from investment activities[60] - Investment income was RMB 733,004.45, accounting for 0.29% of total profit, mainly due to cash dividends received from Note Health[61] - Asset impairment loss was RMB -116,745,988.41, accounting for -46.97% of total profit, mainly due to goodwill impairment of Trividia and inventory write-downs[61] - Other income was RMB 82,172,941.15, accounting for 33.06% of total profit, mainly due to software tax refunds and government subsidies[61] - The company provided a mortgage guarantee of RMB 155,695,534.33 for its subsidiary Changsha Xinnuo Health Industry Investment Co., Ltd., with the guarantee period ending on February 1, 2025[64] - The company raised RMB 502,649,986.28 through a private placement in 2018, with a net amount of RMB 485,911,986.55 after deducting issuance costs[66] - The company issued convertible bonds totaling RMB 500,000,000.00 in 2020, with a net amount of RMB 490,033,873.32 after deducting issuance costs[67] - The Chronic Disease Health Management Monitoring Product Capacity Expansion Project achieved 100% investment progress with a total investment of RMB 8,522.42[68] - The Smart Health Project (Internet + Biosensing + Health Management) achieved 101.02% investment progress with a total investment of RMB 25,990.39[68] - The CGMS (Continuous Glucose Monitoring System) R&D and Clinical Validation Project achieved 91.95% investment progress with a total investment of RMB 13,919.73[68] - The company invested RMB 496.73 million in cash to subscribe to an additional registered capital of RMB 33.91 million in Changsha Sinocare Health Industry Investment Co., Ltd., holding 55% of its shares[85] - The company invested RMB 496,732,672 to acquire a 55% stake in Changsha Xinnuo Health Industry Investment Co., Ltd, making it a subsidiary and consolidating it into the financial statements[98] - Changsha Funuo Medical Technology Co., Ltd received an investment of RMB 27,000,000, with the company contributing RMB 5,400,000 and EOFlow Co., Ltd contributing RMB 3,600,000[98] - Total investment in the two companies amounted to RMB 523,732,672[98] - In 2018, the company raised RMB 50,265 million through a private placement, with a net amount of RMB 48,591.2 million, and RMB 14,340.05 million (28.53%) of the funds were repurposed[101] - In 2020, the company raised RMB 50,000 million through a public offering of convertible bonds, with a net amount of RMB 49,003.39 million, and no funds were repurposed[101] - The total raised funds from both offerings amounted to RMB 100,265 million, with RMB 14,340.05 million (14.30%) repurposed and RMB 2,300.01 million still unused[101] - Prior to the 2018 fundraising, the company used RMB 1,802.06 million of its own funds to pre-invest in the projects, which was later replaced with the raised funds[102] - The company has unused raised funds of RMB 18.56 million and RMB 4.44 million, stored in specific bank accounts for future use[106] - The company has completed the construction of new production capacity for chronic disease health management monitoring products, with remaining funds redirected to the CGMS (Continuous Glucose Monitoring System) R&D and clinical validation project[106] - The CGMS (Continuous Glucose Monitoring System) capacity construction project has a planned investment of 15,000万元, with 14,848.51万元 already invested, achieving 98.99% of the planned investment[123] - The supplementary working capital project has a planned investment of 9,003.39万元, with 9,004.79万元 already invested, exceeding the planned investment by 100.02%[123] - The total planned investment for all projects is 97,594.59万元, with 97,511.97万元 already invested, achieving nearly 100% of the planned investment[123] - The CGMS (Continuous Glucose Monitoring System) clinical trials and international registration work have been delayed, with the expected completion date extended to December 2024[123] - The iPOCT (Intelligent Point-of-Care Testing) product capacity expansion project and CGMS capacity construction project have been delayed, with the expected completion date extended to January 2024[123] - The company's subsidiary, Xinno Health, generated revenue of 106,585.81万元 in the reporting period, contributing to an increase in goodwill of 71,223.81万元 and a negative impact on net profit of 17,994.85万元[130] - The company's subsidiary, Changsha Sinocare Health Industry Investment Co., Ltd., reported a net loss of 179.9 million RMB in 2023[135] - The company's subsidiary, Sinocare Health Management Co., Ltd., achieved a net profit of 49.48 million RMB in 2023[135] Strategic Initiatives and Future Plans - The company's "One Sinocare" initiative aims to integrate all subsidiaries under a unified mission, vision, and values while maintaining operational independence[15] - The company aims to enhance production quality and service efficiency while optimizing its global supply chain to improve competitiveness[2] - The company's CGM product launch marks the beginning of its second growth curve, aiming to become a global leader in diabetes digital management[34] - The company is leveraging biosensor, IoT, and AI technologies to provide smarter and more convenient diabetes management solutions[34] - The company is focused on expanding its existing business while building a user base through CGM direct connections[34] - The company plans to achieve revenue of RMB 4.6 billion in 2024, aiming for steady growth in overall sales and operating profit[115] - The company will focus on digital transformation to provide precise services for diabetic patients, aiming to standardize the diagnosis and treatment process[118] - The company aims to expand its market share in diabetes and related chronic disease detection, enhancing its product and service capabilities[116] - The company will continue to strengthen its global presence, particularly in the CGM (Continuous Glucose Monitoring) market, with plans for full-channel sales in China, Europe, and Southeast Asia, and clinical registration in the U.S.[114] - The company is committed to maintaining high-quality standards, with a focus on global compliance and continuous improvement of its quality management system[118] - The company will continue to innovate and develop new products and technologies, particularly in the field of diabetes management, to enhance its competitive edge globally[114] - The company aims to focus on the development strategy of becoming a "global leader in diabetes digital management" amidst global aging and diabetes challenges[136] - The company plans to promote the digital transformation of diabetes management experts and accelerate global collaboration to drive the formation of the second curve[137] - The company will continue to innovate in 2024, focusing on professionalization, digitalization, and globalization, and enhancing R&D efforts to provide valuable products and services[143] - The company aims to expand into global emerging markets, deepen the precision cultivation model, and promote collaboration among Sinocare, PTS, and Trividia's global marketing systems[150] - The company plans to transition from BGM to BXM, expand from POCT to PDL (Precision Desk Lab), and from CGM to PWS (Precision Wearable System) to manage chronic diseases more effectively[152] - The company will increase R&D investment to accumulate product and technology reserves, achieve product iteration and upgrade, improve production management systems, enhance efficiency, reduce costs, optimize product quality, and strengthen product and brand marketing to improve customer experience[155] - The company is actively addressing risks from industry policy changes by strengthening risk management, optimizing marketing systems, and increasing investment in emerging markets and product R&D[159] - The company is integrating overseas acquisitions Trividia and PTS, focusing on cultural, operational, and business synergies, but faces challenges in managing cultural differences and operational complexities[159] - The company is expanding its clinical market with products like the "Gold" series, dual-function products, iPOCT detection systems, and diabetes digital health management systems, gaining recognition from hospitals and primary care institutions[168] - The company is accelerating the development of primary healthcare services, expanding POCT product sales, and exploring online and offline chronic disease management services for primary healthcare institutions[168] - The company is actively expanding overseas markets, establishing subsidiaries in Vietnam, Philippines, Indonesia, India, Bangladesh, and Thailand, and leveraging PTS and Trividia to explore markets in North America, Europe, and other regions[168] - The company is expanding its multi-indicator detection system and minute diagnosis system to grassroots medical institutions, leveraging 5G technology and internet-based remote quality control to enhance service efficiency and response times[170] - The company is focusing on digital transformation to improve operational efficiency and quality, while also enhancing organizational management through cultural and global collaboration initiatives[173] - To mitigate quality control and product liability risks, the company is increasing automation in production lines, improving internal quality audit systems, and strengthening employee quality awareness[174] - The company is collaborating with Trividia and PTS in the U.S. to deepen cooperation in product R&D and large-scale production, aiming to master core technologies and adapt to market and policy changes[176] - The company is addressing the risk of overseas M&A integration by establishing collaborative mechanisms with overseas subsidiaries, focusing on operational management, product R&D, and international market expansion[179] - The company has been recognized as a "National Enterprise Technology Center" and "National Green Factory," and has received multiple national innovation fund supports, along with ISO13485 and CE certifications[184] - The company has transitioned from a blood glucose monitoring system provider to a provider and service provider of chronic disease point-of-care testing (POCT) products through global collaboration with overseas subsidiaries[185] - The company is leveraging AI and AIGC to enhance overall efficiency and address uncertainties in the competitive business environment[198] R&D and Technological Advancements - R&D investment in 2023 reached 356.41 million yuan, accounting for 8.78% of revenue, up from 7.75% in 2022 and 6.88% in 2021[35] - The company's production line automation rate exceeds 90%, significantly improving manufacturing capabilities and intelligent management levels[138] - The company is leveraging biosensor, IoT, and AI technologies to provide smarter and more convenient diabetes management solutions[34] - The company is focusing on digital transformation, connecting instruments with users, users with data, and data with health service providers to offer comprehensive health management services for diabetes and chronic disease patients[193] - The company is leveraging AI and AIGC to enhance overall efficiency and address uncertainties in the competitive business environment[198] Market Trends and Industry Analysis - The global blood glucose monitoring market grew from $17.5 billion in 2015 to $32.4 billion in 2022, with a CAGR of 9.2%, while China's market reached 12.96 billion yuan, a 14.79% YoY increase[39] - The global CGM market is dominated by Dexcom, Abbott, and Medtronic, with domestic CGM product approvals accelerating significantly since 2021[40] - The global aging population and unhealthy lifestyles are driving increased demand for lipid and glucose monitoring, with POCT technology advancements expected to boost the industry[86] Subsidiaries and Acquisitions - The company established SINOCARE MEDICAL (SINGAPORE) PTE. LTD. and acquired SINOCARE VIETNAM L&M COMPANY LIMITED to meet the demand in the Southeast Asian market and enhance international competitiveness[128] - The company's subsidiary, Xinno Health, became a wholly-owned subsidiary, aligning with the company's strategic development plan and expanding its industrial layout[128] - The company's subsidiary, Changsha Sinocare Health Industry Investment Co., Ltd., reported a net loss of 179.9 million RMB in 2023[135] - The company's subsidiary, Sinocare Health Management Co., Ltd., achieved a net profit of 49.48 million RMB in 2023[135] Operational Efficiency and Automation - The company's domestic factory has achieved large-scale automated production by leveraging the automation experience of its overseas subsidiaries PTS and Trividia[8] - The company's production line automation rate exceeds 90%, significantly improving manufacturing capabilities and intelligent management levels[138] - To mitigate quality control and product liability risks, the company is increasing automation in production lines, improving internal quality audit systems, and strengthening employee quality awareness[174] Financial and Investment Risks - The company is actively addressing risks from industry policy changes by strengthening risk management, optimizing marketing systems, and increasing investment in emerging markets and product R&D[159] - The company is integrating overseas acquisitions Trividia and PTS, focusing on cultural, operational, and business synergies, but faces challenges in managing cultural differences and operational complexities[159] - The company is addressing the risk of overseas M&A integration by establishing collaborative mechanisms with overseas subsidiaries, focusing on operational management, product R&D, and international market expansion[179] Sales and Distribution Strategy - The company's sales strategy combines direct sales and distribution, primarily targeting the retail market through partnerships with pharmaceutical companies, pharmacies, and e-commerce platforms[139] - The company is accelerating the development of primary healthcare services, expanding POCT product sales, and exploring online and offline chronic disease management services for primary healthcare institutions[168] Regulatory and Compliance - The company has obtained multiple international certifications,

假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开 第五届董事会第十次会议、第五届监事会第九次会议，审议并通过《关于 2023 年度计提信用减值损失和资产减值损失的议案》。现将公司本次计提信用减值和 资产减值损失的具体情况公告如下： | 证券代码：300298 | 证券简称：三诺生物 公告编号：2024-033 | | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | 三诺生物传感股份有限公司 关于计提信用减值损失和资产减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 一、本次计提信用减值损失及资产减值损失情况概述 （一）计提减值损失的原因 依据《企业会计准则》及会计政策的相关规定，本着谨慎性原则，公司对截 至 2023 年 12 月 31 日合并财务报表范围内存在减值迹象的资产（范围包括应收 款项、存货、固定资产、在建工程、无形资产以及商誉等）进行了全面清查，并 进行充分的评估和分析，经减值测试，部分资产存在减值，本着谨慎性原则，公 司对截至 2023 年 12 月 31 日存在减值 ...

2024 年 04 月 三诺生物传感股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 三诺生物传感股份有限公司 2024 年第一季度报告 是 □否 追溯调整或重述原因 3 （三） 主要会计数据和财务指标发生变动的情况及原因 2、利润表项目 三诺生物传感股份有限公司 2024 年第一季度报告 二、股东信息 三诺生物传感股份有限公司 2024 年第一季度报告 上述股东关联关系或一致行 外，公司未知其他股东之间是否存在关联关系或一致行动关系。 持股 5%以上股东、前 10 名股东及前 10 名无限售流通股股东参与转融通业务出借股份情况 适用 □不适用 三诺生物传感股份有限公司 2024 年第一季度报告 （二） 前 10 名股东中存在回购专户的特别说明 （四） 限售股份变动情况 三诺生物传感股份有限公司 2024 年第一季度报告 适用 □不适用 8 2、可转换公司债券情况 公司于 2017 年 1 月 24 日召开第三届董事会第二次会议、第三届监事会第二次会议、于 2017 年 2 月 10 日召开 2017 年第一次临时股东大会，审议 ...

中信证券股份有限公司 根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》、《关于募集资金投资项目延期的公告》（公告编号：2023-019），本次向不特 定对象发行可转换公司债券募集资金扣除相关中介费用后，将用于募集资金投资项目 的具体情况如下： 单位：人民币/万元 | 序 | 项目 | 实施主体 | 项目投资总额 | 募集资金承 | 项目达到预定可 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 诺投资总额 | 使用状态日期 | | 1 | iPOCT（智慧化即时检测） 产品产能扩建项目 | 三诺生物 | 25,000.00 | 25,000.00 | 2024年1月 | | 2 | CGMS（连续血糖监测系 | 三诺生物 | 16,419.00 | 15,000.00 | 2024年1月 | 1 | 序 | 项目 | 实施主体 | 项目投资总额 | 募集资金承 | 项目达到预定可 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 诺投资总额 | 使用状态日期 | | | ...

三诺生物传感股份有限公司 三诺生物传感股份有限公司 2024 年度董事、监事及高级管理人员津贴和薪酬方案 鉴于《关于〈公司 2024 年度董事津贴和薪酬方案〉的议案》、《关于〈公 司 2024 年度监事津贴和薪酬方案〉的议案》涉及全体董事、监事的津贴和薪酬， 基于谨慎考虑，全体董事、监事一致决定回避表决，直接提交公司 2023 年年度 股东大会审议。 为充分调动公司董事、监事、高级管理人员工作积极性和创造性，促进公司 稳定、可持续发展，根据《公司章程》等公司制度的有关规定，结合公司实际经 营情况及行业、地区薪酬水平，公司制定了《2024 年度董事、监事及高级管理人 员津贴和薪酬方案》，具体情况公告如下： 一、适用对象 公司的董事、监事及高级管理人员。 二、适用期限 2024 年 1 月 1 日至 2024 年 12 月 31 日。 三、津贴和薪酬标准 1、董事 （1）在公司任职的董事按其所担任的管理职务以及在实际工作中的履职能 力和工作绩效领取相应的薪酬福利，不再另行领取董事津贴。 （2）未在公司担任管理职务的董事以及独立董事在公司领取固定董事津贴， 津贴标准为每人每年税前 12 万元人民币。 2、监事 三诺 ...